A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

PURPOSE: This was a phase I trial to determine the maximum tolerated dose and toxicity of deforolimus (AP23573, MK-8669), an inhibitor of mammalian target of rapamycin (mTOR). The pharmacokinetics, pharmacodynamics, and antineoplastic effects were also studied. EXPERIMENTAL DESIGN: Deforolimus was a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hartford, Christine M., Desai, Apurva A., Janisch, Linda, Karrison, Theodore, Rivera, Victor M., Berk, Lori, Loewy, John W., Kindler, Hedy, Stadler, Walter M., Knowles, Heather L., Bedrosian, Camille, Ratain, Mark J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147153/
https://ncbi.nlm.nih.gov/pubmed/19228743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados